Akeega (Niraparib/Abiraterone) Patent Expiration, LOE Window & CMS Spending

Akeega (Niraparib/Abiraterone) by Johnson & Johnson: FDA Orange Book core substance LOE 2038-03-27 (last listed 2043-09-30), 0 AB generics, $5.7M 2024 CMS Part D & Medicaid spend, and $18,750 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN216793 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-03-27
Last Listed Patent or Exclusivity Date2043-09-30
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.7M
2024 Medicare Part D Spend$5.7M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,750 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.